For the treatment of metastatic EGFRm NSCLC

First-line TAGRISSO nearly doubled median PFS1

First-line TAGRISSO cut the risk of progression or death by 54% vs EGFR TKI comparator1

Median PFS was 18.9 months for patients taking TAGRISSO compared to 10.2 months for an EGFR TKI Comparator Median PFS was 18.9 months for patients taking TAGRISSO compared to 10.2 months for an EGFR TKI Comparator

*In the FLAURA study, all US patients in the comparator arm received erlotinib.2

Overall survival data were not mature at the time of the final PFS analysis1

DEATHS BY TREATMENT ARM3

TAGRISSO efficacy across various subgroups TAGRISSO efficacy across various subgroups

First-line TAGRISSO delivered consistent results across all patient types3

First-line TAGRISSO reduced the risk of progression or death across all prespecified subgroups*, including patients with or without CNS metastases3

TAGRISSO efficacy across various subgroups TAGRISSO efficacy across various subgroups

*Exploratory analysis.

All patient samples were EGFR positive by tissue biopsy.1,3

Adapted from: Soria et al. N Engl J Med. 2018.

First-line TAGRISSO overall response rate and duration of response

Nearly 8 of 10 patients had a response on first-line TAGRISSO1

OVERALL RESPONSE RATE

TAGRISSO had a response rate of 77% TAGRISSO had a response rate of 77%

Patients experienced a durable response on first-line TAGRISSO1

MEDIAN DURATION OF RESPONSE

TAGRISSO® (osimertinib) duration TAGRISSO® (osimertinib) duration

First-line TAGRISSO CNS response

CNS overall response rate by BICR in patients with measurable CNS lesions at baseline1*

TAGRISSO efficacy across various subgroups TAGRISSO efficacy across various subgroups

*According to RECIST v1.1.

Based on confirmed response.

Duration of CNS response by BICR1

TAGRISSO efficacy across various subgroups TAGRISSO efficacy across various subgroups

Based on patients with response only; DOR defined as the time from the date of first documented response (complete response or partial response) until progression or death event.

FLAURA: A phase 3, double-blind, randomized trial1-3

FLAURA Study Design for TAGRISSO
FLAURA Study Design for TAGRISSO

Crossover was allowed for patients in the EGFR TKI comparator arm upon confirmed progression and EGFR T790M positivity

Primary endpoint: PFS based on investigator assessment (according to RECIST v1.1)

Secondary endpoints: overall survival, duration of response, and overall response rate

*Patients received either erlotinib or gefitinib as the sole comparator preselected by the trial site. All US patients in the comparator arm received erlotinib.2

RECIST v1.1 assessment every 6 weeks (± 1 week) until objective progressive disease. Every 12 weeks (± 1 week) after 18 months.2

View full FLAURA study design on ClinicalTrials.gov

FLAURA BASELINE DEMOGRAPHICS1,3

Demographics of patients who participated in FLAURA clinical trial Demographics of patients who participated in FLAURA clinical trial

Includes extrathoracic metastases.

§Identified by CNS lesion site at baseline, medical history, and/or prior surgery, and/or prior radiotherapy to CNS metastases.

Osimertinib (TAGRISSO) is an NCCN-recommended first-line therapy option for newly diagnosed patients with metastatic EGFRm NSCLC4

Click here to view information about AURA3 data VIEW FIRST-LINE SAFETY

References: 1. TAGRISSO [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2018. 2. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378(2):113-125 [protocol]. 3. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378(2):113-125. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC V.3.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed March 1, 2018. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. To view the most recent and complete version of the guideline, go online to NCCN.org.

Important Safety Information Expand

  • There are no contraindications for TAGRISSO

  • Interstitial lung disease (ILD)/pneumonitis occurred in 3.9% of the 1142 TAGRISSO-treated patients; 0.4% of cases were fatal. Withhold TAGRISSO and promptly investigate for ILD in patients who present with worsening of respiratory symptoms which may be indicative of ILD (eg, dyspnea, cough and fever). Permanently discontinue TAGRISSO if ILD is confirmed

  • Heart rate-corrected QT (QTc) interval prolongation occurred in TAGRISSO-treated patients. Of the 1142 TAGRISSO-treated patients in clinical trials, 0.9% were found to have a QTc > 500 msec, and 3.6% of patients had an increase from baseline QTc > 60 msec. No QTc-related arrhythmias were reported. Conduct periodic monitoring with ECGs and electrolytes in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval. Permanently discontinue TAGRISSO in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia

  • Cardiomyopathy occurred in 2.6% of the 1142 TAGRISSO-treated patients; 0.1% of cardiomyopathy cases were fatal. A decline in left ventricular ejection fraction (LVEF) ≥10% from baseline and to <50% LVEF occurred in 3.9% of 908 patients who had baseline and at least one follow-up LVEF assessment. Conduct cardiac monitoring, including assessment of LVEF at baseline and during treatment, in patients with cardiac risk factors. Assess LVEF in patients who develop relevant cardiac signs or symptoms during treatment. For symptomatic congestive heart failure, permanently discontinue TAGRISSO

  • Keratitis was reported in 0.7% of 1142 patients treated with TAGRISSO in clinical trials. Promptly refer patients with signs and symptoms suggestive of keratitis (such as eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or red eye) to an ophthalmologist

  • Verify pregnancy status of females of reproductive potential prior to initiating TAGRISSO. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the final dose. Advise males with female partners of reproductive potential to use effective contraception for 4 months after the final dose

  • Most common adverse reactions (≥20%) were diarrhea, rash, dry skin, nail toxicity, stomatitis, fatigue and decreased appetite

Indications

  • TAGRISSO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test

  • TAGRISSO is indicated for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy


Please see complete Prescribing Information including Patient Information.

You may report side effects related to AstraZeneca products by clicking here.

read more